文献速递皮肤肿瘤

选择性USP7抑制与MEK1/2抑制剂协同增强NRAS突变黑色素瘤免疫应答并增效抗PD-1治疗

Selective USP7 Inhibition Synergizes with MEK1/2 Inhibitor to Enhance Immune Responses and Potentiate Anti-PD-1 Therapy in NRAS-Mutant Melanoma.
PubMed 文献 · J Invest Dermatol · 2025-04-09

NRAS突变黑色素瘤靶向治疗仍为未满足的临床需求。研究发现选择性USP7抑制剂FT671可抑制NRAS突变黑色素瘤细胞系增殖,其疗效依赖功能性p53信号通路激活;FT671与MEK1/2抑制剂联用具有协同作用,在免疫健全小鼠中增强瘤内免疫细胞浸润,三者联合抗PD-1抗体可实现持久肿瘤消退。

要点

  • USP7抑制剂FT671抑制NRAS突变黑色素瘤细胞增殖,疗效依赖p53通路激活。
  • FT671与MEK1/2抑制剂协同诱导细胞焦亡并增强抗肿瘤免疫。
  • 三联USP7i+MEK1/2i+抗PD-1实现持久肿瘤消退,停药后效应持续超80天。

核心结论

  • USP7抑制剂联合MEK1/2抑制剂是靶向NRAS突变黑色素瘤的有前景策略,并为联合抗PD-1辅助治疗提供依据。

研究设计与样本

  • 研究采用NRAS突变黑色素瘤细胞系、同种移植模型及免疫健全小鼠模型,评估USP7抑制剂FT671单用及联合MEK1/2抑制剂和抗PD-1抗体的效果。

主要发现

  • FT671抑制NRAS突变黑色素瘤细胞系增殖,敲除TP53BP1、TP53或CDKN1A导致对FT671耐药。
  • 在Nras突变黑色素瘤同种移植模型中,FT671治疗延迟肿瘤生长。
  • FT671与MEK1/2抑制剂联合在体外协同并诱导细胞焦亡。
  • 免疫健全小鼠中联合治疗显著抑制肿瘤生长、延长生存并增强瘤内免疫细胞浸润,尤其提高CD8+ T细胞和成熟树突状细胞比例。
  • USP7i、MEK1/2抑制剂和抗PD-1抗体三联治疗实现持久肿瘤消退,停药后效应持续超过80天。

临床怎么用

  • 提示USP7抑制剂联合MEK1/2抑制剂可作为NRAS突变黑色素瘤的潜在靶向策略,并可能作为辅助治疗增强抗PD-1免疫疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Targeted therapy for NRAS-mutant melanoma remains an unmet clinical need. We found that inhibiting USP7 with the selective ubiquitin-specific protease 7 inhibitor (USP7i) FT671 inhibited cell proliferation in NRAS-mutant melanoma cell lines. In addition, we identified and validated that knockout of TP53BP1, TP53, or CDKN1A conferred resistance to FT671, suggesting that the activation of a functional p53 signaling pathway is essential for the efficacy of USP7i. In Nras-mutant melanoma isograft models, FT671 treatment delayed tumor growth. Moreover, the combinatorial treatment with FT671 and MAPK/(extracellular signal-regulated kinase) kinase 1/2 inhibitor was synergistic and induced pyroptosis in vitro. In immunocompetent mice, the combined treatment profoundly suppressed tumor growth, prolonged survival, and enhanced intratumoral immune cell infiltration, particularly increasing the ratios of CD8+ T cells and mature dendritic cells, indicative of activated antitumor immunity. Notably, the triple combination of USP7i, MAPK/(extracellular signal-regulated kinase) kinase 1/2 inhibitor, and anti-PD-1 antibody resulted in durable tumor regression, with effects persisting beyond 80 days after treatment cessation. These findings establish USP7i + MAPK (extracellular signal-regulated kinase) kinase 1/2 inhibitor as a promising strategy for targeting NRAS, an 'undruggable' mutation in melanoma, and provide a strong rationale for the clinical development of USP7i plus MAPK (extracellular signal-regulated kinase) kinase 1/2 inhibitor as an adjuvant therapy to enhance anti-PD-1 immunotherapy in patients with NRAS-mutant melanoma.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Su L, Wang D, Purwin TJ, et al. Selective USP7 Inhibition Synergizes with MEK1/2 Inhibitor to Enhance Immune Responses and Potentiate Anti-PD-1 Therapy in NRAS-Mutant Melanoma. J Invest Dermatol. 2025. PMID: 40204067. doi:10.1016/j.jid.2025.03.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。